476 related articles for article (PubMed ID: 18366508)
1. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain.
Webster LR; Fakata KL; Charapata S; Fisher R; MineHart M
Pain Med; 2008 Apr; 9(3):282-90. PubMed ID: 18366508
[TBL] [Abstract][Full Text] [Related]
2. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain.
Wallace MS; Kosek PS; Staats P; Fisher R; Schultz DM; Leong M
Pain Med; 2008 Apr; 9(3):271-81. PubMed ID: 18366507
[TBL] [Abstract][Full Text] [Related]
3. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice.
Alicino I; Giglio M; Manca F; Bruno F; Puntillo F
Pain; 2012 Jan; 153(1):245-249. PubMed ID: 22082570
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal ziconotide and opioid combination therapy for noncancer pain: an observational study.
Deer TR; Kim C; Bowman R; Tolentino D; Stewart C; Tolentino W
Pain Physician; 2009; 12(4):E291-6. PubMed ID: 19668287
[TBL] [Abstract][Full Text] [Related]
5. Ziconotide: new drug. Limited analgesic efficacy, too many adverse effects.
Prescrire Int; 2008 Oct; 17(97):179-82. PubMed ID: 19530373
[TBL] [Abstract][Full Text] [Related]
6. Long-term intrathecal ziconotide for chronic pain: an open-label study.
Webster LR; Fisher R; Charapata S; Wallace MS
J Pain Symptom Manage; 2009 Mar; 37(3):363-72. PubMed ID: 18715748
[TBL] [Abstract][Full Text] [Related]
7. The Relationship Between the Mechanisms of Action and Safety Profiles of Intrathecal Morphine and Ziconotide: A Review of the Literature.
Webster LR
Pain Med; 2015 Jul; 16(7):1265-77. PubMed ID: 25645109
[TBL] [Abstract][Full Text] [Related]
8. Ziconotide: A rapid detoxification protocol for the conversion from intrathecal morphine--the Raffaeli Detoxification Model.
Raffaeli W; Righetti D; Sarti D; Balestri M; Ferioli I; Monterubbianesi MC; Caminiti A
J Opioid Manag; 2011; 7(1):21-6. PubMed ID: 21434581
[TBL] [Abstract][Full Text] [Related]
9. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial.
Staats PS; Yearwood T; Charapata SG; Presley RW; Wallace MS; Byas-Smith M; Fisher R; Bryce DA; Mangieri EA; Luther RR; Mayo M; McGuire D; Ellis D
JAMA; 2004 Jan; 291(1):63-70. PubMed ID: 14709577
[TBL] [Abstract][Full Text] [Related]
10. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain.
Atanassoff PG; Hartmannsgruber MW; Thrasher J; Wermeling D; Longton W; Gaeta R; Singh T; Mayo M; McGuire D; Luther RR
Reg Anesth Pain Med; 2000; 25(3):274-8. PubMed ID: 10834782
[TBL] [Abstract][Full Text] [Related]
11. Bolus intrathecal injection of ziconotide (Prialt®) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) system: a pilot study.
Mohammed SI; Eldabe S; Simpson KH; Brookes M; Madzinga G; Gulve A; Baranidharan G; Radford H; Crowther T; Buchser E; Perruchoud C; Batterham AM
Neuromodulation; 2013; 16(6):576-81; discussion 582. PubMed ID: 23205907
[TBL] [Abstract][Full Text] [Related]
12. Intrathecal Pharmacology Update: Novel Dosing Strategy for Intrathecal Monotherapy Ziconotide on Efficacy and Sustainability.
Pope JE; Deer TR
Neuromodulation; 2015 Jul; 18(5):414-20. PubMed ID: 25708382
[TBL] [Abstract][Full Text] [Related]
13. Ziconotide--a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain--a short review.
Klotz U
Int J Clin Pharmacol Ther; 2006 Oct; 44(10):478-83. PubMed ID: 17063978
[TBL] [Abstract][Full Text] [Related]
14. Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics.
Sanford M
CNS Drugs; 2013 Nov; 27(11):989-1002. PubMed ID: 23999971
[TBL] [Abstract][Full Text] [Related]
15. Ziconotide: an update and review.
Williams JA; Day M; Heavner JE
Expert Opin Pharmacother; 2008 Jun; 9(9):1575-83. PubMed ID: 18518786
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.
Rauck RL; Wallace MS; Leong MS; Minehart M; Webster LR; Charapata SG; Abraham JE; Buffington DE; Ellis D; Kartzinel R;
J Pain Symptom Manage; 2006 May; 31(5):393-406. PubMed ID: 16716870
[TBL] [Abstract][Full Text] [Related]
17. Italian registry on long-term intrathecal ziconotide treatment.
Raffaeli W; Sarti D; Demartini L; Sotgiu A; Bonezzi C;
Pain Physician; 2011; 14(1):15-24. PubMed ID: 21267038
[TBL] [Abstract][Full Text] [Related]
18. Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol.
Dupoiron D; Bore F; Lefebvre-Kuntz D; Brenet O; Debourmont S; Dixmerias F; Buisset N; Lebrec N; Monnin D
Pain Physician; 2012; 15(5):395-403. PubMed ID: 22996851
[TBL] [Abstract][Full Text] [Related]
19. Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options.
Deer TR; Pope JE; Hanes MC; McDowell GC
Pain Med; 2019 Apr; 20(4):784-798. PubMed ID: 30137539
[TBL] [Abstract][Full Text] [Related]
20. Ziconotide: a clinical update and pharmacologic review.
Pope JE; Deer TR
Expert Opin Pharmacother; 2013 May; 14(7):957-66. PubMed ID: 23537340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
